We have a lot of safeguards that our institutions create to make sure we have thorough evaluation and assessment of the different options. In a public health emergency, we need to do a reassessment of those risk and benefit equations.
In the case of depot naltrexone, this is a molecule that would block opioid receptors. It would allow us to treat, for example, as we were discussing before, people who have not developed an opioid use disorder but are in the initial stages of that. They are being exposed systematically to overdoses, either by seeking them out or through the contamination of the supply. They would benefit from blocking those receptors, because, let's say, they are young and their brains are developing.